Clinical Trial Update: Proof of Mechanism Study of GSK2330811 in Diffuse Cutaneous Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 proof-of-mechanism study of GSK2330811 in diffuse cutaneous systemic sclerosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Scleroderma
• Systemic Sclerosis

Drugs mentioned

• GSK2330811 (GSK2330811)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Scleroderma, Systemic | Phase 2 | Status: COMPLETED | Results posted: 2021-05-24